ClinicalTrials.gg
CompletedNCT05376969ENHANCE-MEXTUpdated Oct 25, 2022

Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin

A Phase 3 interventional study of DWP16001 in T2DM (Type 2 Diabetes Mellitus), sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-25.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2021, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
159
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.

Enrollment
7th of 15
159 · median 140
Started
2021
with 1 other
Phase 3
8 of 15
3 open now
Registered
5th of 15
by date
Lead sponsor
12 of 15
Daewoong Pharmaceutical Co. LTD.

Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 8 in phase 3, and was the 5th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About enavogliflozin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A Multi-center, Open-label, Extension study to Evaluate the long term Safety and Efficacy of DWP16001 add-on to metformin in Patients with type 2 diabetes mellitus inadequately controlled on metformin

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participated in the prior phase 3 study (Protocol No: DW_DWP16001302) for meeting the inclusion criteria and completed the study
  • Voluntarily decided to participate in the extension study and provided a written consent on the consent form

Exclusion criteria

Exclusion Criteria:

  • Withdrawn from the prior phase 3 study (Protocol No: DW_DWP16001302) or expected of having safety issue if taking part in the study in the judgment of the investigator
  • Subjects with the following diseases or signs:

    • Diabetic ketoacidosis
    • Moderate to severe renal impairment (estimated [eGFR] \< 60 mL/min/1.73 m2
  • Females who are pregnant or breast-feeding, or subjects who do not agree to the use of appropriate methods throughout the study

Subjects must agree to one of the following appropriate contraceptive methods for subjects or their partners:

① Either surgical sterilization (vasectomy, etc.) or insertion of an intrauterine device (copper loop, intrauterine hormone-containing system), or

② A physical barrier method combined with either systemic hormonal contraceptives or spermicide, or

③ Use of male condom combined with either cervical cap or diaphragm Determined to be ineligible for the study by the investigator, besides the above

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    DWP16001 Amg

    DWP16001 Amg, Tablets, Orally, Once daily

    Drug: DWP16001

Interventions

06

What researchers measure

Primary outcomes

  1. Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP

    \*Hypoglycemia, urinary tract infection, genital infection, pollakiuria, or polyuria

    Time frame: at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP

Secondary outcomes

  1. Changes from baseline* in HbA1c at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP

    \* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)

    Time frame: at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP

  2. Changes from baseline* in FPG at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP

    \* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)

    Time frame: at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP

  3. Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP

    \* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001302)

    Time frame: at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP

07

Study locations

1 site
  • Daewoong pharmatceutical
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in May 2022, 11 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2022
First posted
May 17, 2022
StartActual
May 25, 2021
Primary completionActual
May 16, 2022
CompletionActual
May 16, 2022
Last update
Oct 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05376969
Responsible party
Sponsor
First posted
May 17, 2022
Start date
May 25, 2021
Primary completion
May 16, 2022
Completion
May 16, 2022
Last update
Oct 25, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion